CD300E and type 2 diabetes mellitus: A significantly higher titre of anti-CD300e antibody was detected in sera from FT1D patients in the acute phase (versus T1AD patients; P = 0.0021, versus T2D patients; P = 0.0002, versus AITD patients; P = 0.0006, versus HC; P<0.0001), and also in sera from FT1D patients both in the sub-acute phase (versus T2D patients; P = 0.0070, versus AITD patients; P = 0.0035, versus HC; P<0.0001) and that in the chronic phase (versus T2D patients; P = 0.0043, versus AITD patients; P = 0.0017, versus HC; P<0.0001) (Fig 2A).